Last reviewed · How we verify
VIAject®25
At a glance
| Generic name | VIAject®25 |
|---|---|
| Sponsor | Biodel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus (NA)
- Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes (PHASE2)
- Efficacy of Educational Nutrition and Exercise on the Regulation of Appetite Through Exosomes in Type 2 Diabetics (NA)
- CArbohydrate Loading in Aortic Surgery (NA)
- Dexmedetomidine and Fentanyl As Adjuvants to Hyperbaric Bupivacaine for the Prevention of Post-spinal Shivering in Hip Arthroplasty Surgeries (NA)
- High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes (NA)
- Sympathetic Activation in Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIAject®25 CI brief — competitive landscape report
- VIAject®25 updates RSS · CI watch RSS
- Biodel portfolio CI